Expert De Novo Biosimilar Monoclonal Antibody Sequencing Service

Background Solution Workflow Application Advantage Related Services FAQ Online Inquiry

In the competitive landscape of biopharmaceuticals, the development of biosimilar monoclonal antibodies (mAbs) demands absolute precision. Establishing sequence identity with the innovator molecule is not just a regulatory requirement; it is the foundational pillar of a successful biosimilar program. Any ambiguity in the primary amino acid sequence can lead to costly delays, failed clinical trials, and significant intellectual property (IP) risks. Creative Biolabs stands at the forefront of protein analytics, offering best-in-class De Novo Biosimilar Monoclonal Antibody Sequencing Services. Leveraging our proprietary platform and over two decades of expertise, we deliver unambiguous, high-resolution sequencing data that empowers your development, accelerates your timeline, and secures your IP position.

Discuss Your Project Today

The Critical Challenge: Why Standard Sequencing Isn't Enough for Biosimilars

The original sequence of an innovator mAb is often proprietary and not publicly available. Even when it is, the process of cell line development, manufacturing, and purification can introduce subtle but critical variations. De novo sequencing—determining the sequence without a reference database—is the only definitive method to:

Confirm Absolute Identity: Prove to regulators that your biosimilar has the same primary amino acid sequence as the reference biologic.
Identify Sequence Variants: Detect and quantify low-abundance variants, such as mutations or host-cell-protein-related sequence errors, that could impact immunogenicity and efficacy.
Characterize Post-Translational Modifications (PTMs): Pinpoint and map critical PTMs like glycosylation, oxidation, and deamidation, which are vital for function and stability.
Secure Intellectual Property: Provide the foundational sequence data required for patent applications and freedom-to-operate analyses.

Without a robust De Novo Antibody Sequencing strategy, your biosimilar program is navigating blind.

Fig. 1 Antibody. (Creative Biolabs Authorized).

Our Solution: The Integrated De Novo Sequencing Platform

At Creative Biolabs, we have engineered a state-of-the-art platform, specifically designed to overcome the challenges of Biosimilar Monoclonal Antibody Sequencing. This multi-engine, mass spectrometry-driven approach guarantees 100% coverage and unparalleled accuracy.

Key Service Features & Advantages	Description
100% Sequence Coverage Guaranteed	By using a multi-enzyme digestion strategy and overlapping peptide mapping, we ensure every single amino acid in both the heavy and light chains is identified and placed correctly.
Unambiguous I/L & Q/K Determination	Our advanced fragmentation methods and sophisticated algorithms definitively distinguish between isobaric residues like Isoleucine/Leucine (I/L) and Glutamine/Lysine (Q/K), eliminating all ambiguity.
High-Resolution PTM & Glycosylation Analysis	We don't just provide the sequence; we provide a comprehensive map of all relevant PTMs and detailed N- and O-linked glycan structures, crucial for demonstrating biosimilarity.
Advanced Mass Spectrometry Fleet	Our labs are equipped with the latest generation of mass spectrometers, providing sub-ppm mass accuracy and exceptional sensitivity.
Proprietary Bioinformatic Pipeline	The platform integrates industry-leading software with our proprietary algorithms for rapid, accurate peptide assembly, PTM identification, and data validation.
Full Variable (V) & Constant (C) Region Sequencing	We provide complete sequencing of the Fab and Fc regions, including the critical CDRs that define antibody specificity and effector functions.
Comprehensive, IP-Ready Reporting	Our final reports are publication- and patent-ready, providing all the data and methodology details needed to support regulatory filings and IP claims.

Our Advanced De Novo Biosimilar mAb Sequencing Workflow

Our workflow is a symphony of meticulous biochemistry and powerful data science, refined over thousands of successful projects.

Step 1: Antibody Purification & Subunit Separation

Process: The supplied antibody sample undergoes rigorous QC and purification using methods like Protein A/G affinity chromatography. The heavy chains (HC) and light chains (LC) are then separated under reducing conditions.
Outcome: Pure, isolated HC and LC populations ready for independent analysis.

Step 2: Multi-Enzyme Digestion

Process: Each chain (HC and LC) is separately digested by a panel of at least six different proteolytic enzymes. This creates a vast library of overlapping peptide fragments.
Outcome: Complete, redundant peptide fragments covering the entire length of each chain.

Step 3: High-Resolution LC-MS/MS Analysis

Process: The peptide mixtures are separated using ultra-high-performance liquid chromatography (UHPLC) and analyzed by our cutting-edge mass spectrometers. The instruments perform data-dependent acquisition, selecting peptide ions for fragmentation (MS/MS) using multiple methods.
Outcome: High-resolution mass spectra for tens of thousands of unique peptides and their fragments.

Step 4: Advanced Bioinformatic Assembly & Validation

Process: This is the core of our platform. The massive MS/MS dataset is processed using a multi-engine approach. De novo sequencing algorithms derive peptide sequences directly from the spectra, which are then assembled into full-length HC and LC sequences using the overlapping data from the different enzyme digests.
Outcome: A single, confirmed, high-confidence sequence for the full heavy and light chains with 100% coverage.

Step 5: PTM Mapping and Reporting

Process: Once the primary sequence is established, the data is re-interrogated to identify and locate all PTMs and glycan structures.
Outcome: A comprehensive, publication-ready report detailing the complete antibody sequence, variant analysis, and a full PTM map.

Applications of De Novo Biosimilar Monoclonal Antibody Sequencing

Our services are pivotal across the entire biosimilar lifecycle:

Early-Stage Development: Confirm the sequence of a candidate clone to ensure it matches the innovator molecule before committing to expensive cell line development.
Cell Line & Process Optimization: Monitor sequence fidelity during process changes to ensure the final product remains consistent.
Full-Scale Biosimilar Characterization: Generate the definitive sequence data package required for regulatory submissions.
Patent Litigation and IP Protection: Provide irrefutable evidence of your molecule's primary structure to support patent claims or defend against infringement.
Antibody Engineering & Reformatting: Use the precise innovator sequence as a template for developing next-generation biobetters.
Manufacturing QC Lot Release: Use the de novo sequence as a "gold standard" reference for peptide mapping in quality control.

Why Choose Creative Biolabs for Your Biosimilar Sequencing Needs?

20+ Years of Specialization: We are not generalists. We have been specialists in antibody engineering and proteomics for over two decades, with a dedicated focus on de novo sequencing.
PhD-Level Project Management: Every project is overseen by a PhD-level scientist who provides expert consultation from initial inquiry to final data delivery.
Proven Track Record: We have successfully sequenced thousands of monoclonal antibodies for clients ranging from academic labs to top-10 global pharmaceutical companies.
Absolute Confidentiality: We operate under strict confidentiality agreements to protect your valuable intellectual property.
Customizable Solutions: We understand that every project is unique. We will work with you to tailor a sequencing strategy that meets your specific antibody, timeline, and budget requirements.

Explore Our Comprehensive Services

To further support your research, Creative Biolabs offers a suite of antibody sequencing related services:

Ready to secure the definitive sequence for your biosimilar monoclonal antibody? Partner with the experts. Contact our team today to discuss your project and receive a customized, no-obligation quote.

Contact Us Today for a Free Quote!

Frequently Asked Questions (FAQs)

Q: How much sample material is required for De Novo Biosimilar mAb Sequencing?

A: We typically require 100-200 µg of purified antibody at a concentration >0.5 mg/mL for our standard workflow. Please contact us to discuss your specific sample.

Q: How do you guarantee 100% coverage and accuracy?

A: The guarantee comes from our multi-enzyme strategy and the depth of our mass spectrometry data. By generating thousands of overlapping peptides, our bioinformatic platform has redundant information to cover every region, including difficult-to-sequence hydrophobic or proline-rich areas. Every residue is confirmed by multiple, independent peptide fragments.

Q: Can you sequence antibodies with complex modifications or from difficult matrices?

A: Yes. Our robust sample preparation and advanced MS techniques are designed to handle complex samples. We can characterize highly glycosylated antibodies, antibody-drug conjugates (ADCs), and even antibodies from challenging matrices, though additional purification steps may be required.

Reference

Japelj, Boštjan, et al. "Biosimilar structural comparability assessment by NMR: from small proteins to monoclonal antibodies." Scientific reports 6.1 (2016): 32201. https://doi.org/10.1038/srep32201

×

Online Inquiry

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.